CM
FDMT icon

Caption Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Caption Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,944
Closed -$216K – 1349
2023
Q2 		$216K Buy
+11,944
New +$220K ﹤0.01% 926

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's FDMT Position: Q3 2023 in Review

Caption Management sold out of 4D Molecular Therapeutics (FDMT) in Q3 2023, closing a stake of 11,944 shares — an estimated $216K sold.

Caption Management first reported a position in FDMT in Q2 2023 and held it in 1 quarter. The position peaked at $216K in Q2 2023. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2023.

  • Caption Management reported no remaining 4D Molecular Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Caption Management sold 11,944 4D Molecular Therapeutics shares in Q3 2023, an estimated $216K.
  • Caption Management first reported a position in 4D Molecular Therapeutics in Q2 2023 and held it in 1 quarter.
  • Caption Management's 4D Molecular Therapeutics position peaked at $216K in Q2 2023.
  • 110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2023.

Based on Caption Management's 13F filing for Q3 2023, filed 14 Nov 2023.